Résumé
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL+ cells during the follow-up of CML could be useful for optimizing therapeutic management. We retrospectively analyzed T315I mutated BCR-ABL clones throughout the CML history of two patients by nested-PCR-RFLP. At the time of progression, the T315I mutation represented 100% of the BCR-ABL transcripts. During follow-up, we showed that (i) despite a molecular response to IM, a high proportion of T315I transcripts were present (>85%) and predictive of relapse, (ii) interruption of IM and switching to other therapies resulted in a significant reduction in mutant transcript level while total BCR-ABL+ transcripts remained stable.
langue originale | Anglais |
---|---|
Pages (de - à) | 1073-1077 |
Nombre de pages | 5 |
journal | Leukemia Research |
Volume | 29 |
Numéro de publication | 9 |
Les DOIs | |
état | Publié - 1 sept. 2005 |
Modification externe | Oui |